CPT Pharmacometrics & Systems Pharmacology · 2015 · 76 citations · 69 references
PharmacyPharmacokineticsPharmacologyDose-response ModelingPharmacokinetic ModelingPharmacokinetic-pharmacodynamic ModelingDose SchedulingExposure-response AnalysisExposure-response ModelingPharmacodynamic ModelingPharmacokinetic SimulationPharmacokinetics Of Anticancer DrugsCancer Drug Response ModelingClinical Pharmacology ReviewCombination TherapyDose-response Model BuildingDosing Regimen SimulationPharmacokinetic-pharmacodynamic Link ModelingPharmacometric SimulationsTherapeutic Index Modeling
Anticancer agents often have a narrow therapeutic index (TI), requiring precise dosing to ensure sufficient exposure for clinical activity while minimizing toxicity. These agents frequently have complex pharmacology, and combination therapy may cause schedule-specific effects and interactions. We review anticancer drug development, showing how integration of modeling and simulation throughout development can inform anticancer dose selection, potentially improving the late-phase success rate. This article has a companion article in Clinical Pharmacology & Therapeutics with practical examples.
69
The Statistical Analysis of Failure Time Data.
Murray Aitkin, John D. Kalbfleisch, Ross L. Prentice · Biometrics · 1981 · 10K citations
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Martine Piccart, Marion Procter, Brian Leyland‐Jones et al. · New England Journal of Medicine · 2005 · 5.1K citations · Full text
Medicine, Oncology, Pharmacology +16
Trastuzumab-Induced Hepatotoxicity: A Case Report
D. Vucicevic, Elizabeth J. Carey, Nina J. Karlin · Breast Care · 2013 · 4.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Phase 3 trial of everolimus for metastatic renal cell carcinoma
Robert J. Motzer, Bernard Escudier, Stéphane Oudard et al. · Cancer · 2010 · 1.1K citations
Medicine, Oncology, Pharmacology +17